Do you want to read an article? Please log in or register.
Household proximity to water and nontuberculous mycobacteria in children with cystic fibrosis.
Related content
Pulmonary Fibrosis
Children with cystic fibrosis demonstrate no respiratory immunological, infective or physiological, consequences of vitamin D deficiency
J Cyst Fibros.
Thursfield RM, Naderi K, Leaver N, Rosenthal M, Alton EWFW, Bush A, Davies JC
doi: 10.1016/j.jcf.2018.02.011.
RECOMMENDED
Pulmonary Fibrosis
Nontuberculous mycobacteria in cystic fibrosis
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Curr Opin Pulm Med
Nick JA, Daley CL, Lenhart-Pendergrass PM, Davidson RM
doi: 10.1097/MCP.0000000000000816
CoughPulmonary Fibrosis
The CF-Sputum Induction Trial (CF-SpIT) to assess lower airway bacterial sampling in young children with cystic fibrosis: a prospective internally controlled interventional trial
Ronchetti K, Tame JD, Paisey C, Thia LP, Doull I, Howe R, Mahenthiralingam E, Forton JT
doi: 10.1016/
Initial acquisition and succession of the cystic fibrosis lung microbiome is associated with disease progression in infants and preschool children
PLoS Pathog.
Muhlebach MS, Zorn BT, Esther CR, Hatch JE, Murray CP, Turkovic L, Ranganathan SC, Boucher RC, Stick SM, Wolfgang MC
doi: 10.1371/
RECOMMENDED
Pulmonary Fibrosis
Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study
Lancet Respir Med.
McNamara JJ, McColley SA, Marigowda G, Liu F, Tian S, Owen CA, Stiles D, Li C, Waltz D, Wang LT, Sawicki GS
doi: 10.1016/S2213-2600(18)30460-0.
Pulmonary Fibrosis
Safety of intravenous tobramycin in combination with a variety of anti-pseudomonal antibiotics in children with cystic fibrosis
SAGE Open Med.
Deschamp AR, Pettit RS, Donaldson JA, Slaven JE, Davis SD
doi: 10.1177/2050312117736694.
RECOMMENDED
Pulmonary Fibrosis
Lung Clearance Index to Track Acute Respiratory Events in School-age Children with Cystic Fibrosis
★ 3
Recommended by
Dr Martin Frey, Faculty Member
Am J Respir Crit Care Med.
Perrem L, Stanojevic S, Shaw M, Jensen R, McDonald N, Isaac SM, Davis M, Clem C, Guido J, Jara S, France L, Solomon M, Grasemann H, Waters V, Sweezey N, Sanders DB, Davis SD, Ratjen F
doi: 10.1164/rccm.202006-2433OC.Visit the original publication at ncbi.nlm.nih.gov
Pulmonary Fibrosis
Impact of a cystic fibrosis transmembrane conductance regulator (CFTR) modulator on high-dose ibuprofen therapy in pediatric cystic fibrosis patients
Pediatr Pulmonol.
Bruch BA, Singh SB, Ramsey LJ, Starner TD
doi: 10.1002/ppul.24024.
Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study
Lancet Respir Med.
Rosenfeld M, Wainwright CE, Higgins M, Wang LT, McKee C, Campbell D, Tian S, Schneider J, Cunningham S, Davies JC; ARRIVAL study group
doi: 10.1016/S2213-